LakeShore Biopharma Co., Ltd. (LSB)
(Delayed Data from NSDQ)
$0.48 USD
+0.01 (1.60%)
Updated Jul 26, 2024 03:55 PM ET
After-Market: $0.48 0.00 (0.52%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum A VGM
Income Statements
Fiscal Year end for LakeShore Biopharma Co, Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 100 | 0 | 0 | NA |
Cost Of Goods | NA | 22 | 0 | 0 | NA |
Gross Profit | NA | 78 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 98 | 0 | 1 | 0 |
Income After Depreciation & Amortization | 0 | -20 | 0 | -1 | 0 |
Non-Operating Income | NA | 4 | 0 | 0 | NA |
Interest Expense | NA | 4 | 0 | 0 | NA |
Pretax Income | NA | -21 | 7 | -1 | NA |
Income Taxes | NA | 0 | 0 | 0 | NA |
Minority Interest | NA | 0 | 0 | 0 | NA |
Investment Gains/Losses | NA | 0 | 0 | 0 | NA |
Other Income/Charges | NA | 0 | 0 | 0 | NA |
Income From Cont. Operations | NA | -21 | 7 | -1 | NA |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | NA |
Net Income (GAAP) | NA | -21 | 7 | -1 | NA |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -15 | 0 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | NA | 5 | 0 | 0 | NA |
Income After Depreciation & Amortization | 0 | -20 | 0 | -1 | 0 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | NA | 5.75 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.03 | NA | NA |
Diluted Net EPS (GAAP) | NA | -0.23 | -0.03 | -0.03 | NA |
Fiscal Year end for LakeShore Biopharma Co, Ltd falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 23.82 | 13.64 | 24.40 |
Cost Of Goods | NA | NA | NA | NA | 4.80 |
Gross Profit | NA | NA | NA | NA | 19.60 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 29.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -9.69 |
Non-Operating Income | NA | NA | NA | NA | 1.10 |
Interest Expense | NA | NA | NA | NA | 1.11 |
Pretax Income | NA | NA | NA | NA | -9.71 |
Income Taxes | NA | NA | NA | NA | -0.08 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | -11.55 | -14.68 | -9.62 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -11.55 | -14.68 | -9.62 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 96.23 | 93.06 | 93.06 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.12 | -0.16 | -0.10 |
Diluted Net EPS (GAAP) | NA | NA | -0.12 | -0.16 | -0.10 |